Balance Sheet
Cash Flow Statement
Daily Values
DMA 100DMA 200DMA 50Dividend YieldEV to CFOEV to EBITEV to EBITDAEV to FCFEnterprise ValueMarket Cap to FCFMarket CapitalizationPricePrice to Earnings
Growth Metrics
Income Statement
Others
Ratios
Assets AverageDebt RatioDebt to EquityEnterprise ValueEquity AverageEquity RatioInterest Coverage RatioInvested CapitalReturn on AssetsReturn on Capital EmployedReturn on EquityTimes Interest Earned

Alx Oncology Holdings (ALXO) Enterprise Value (2019 - 2026)

Alx Oncology Holdings' Enterprise Value history spans 5 years, with the latest figure at -$182.7 million for Q4 2023.

  • On a quarterly basis, Enterprise Value rose 31.36% to -$182.7 million in Q4 2023 year-over-year; TTM through Dec 2023 was -$182.7 million, a 31.36% increase, with the full-year FY2023 number at -$182.7 million, up 31.36% from a year prior.
  • Enterprise Value hit -$182.7 million in Q4 2023 for Alx Oncology Holdings, up from -$190.0 million in the prior quarter.
  • Over the last five years, Enterprise Value for ALXO hit a ceiling of -$9.0 million in Q4 2019 and a floor of -$434.2 million in Q4 2020.
  • Historically, Enterprise Value has averaged -$274.0 million across 5 years, with a median of -$275.6 million in 2022.
  • Biggest five-year swings in Enterprise Value: tumbled 4715.56% in 2020 and later surged 33.31% in 2023.
  • Tracing ALXO's Enterprise Value over 5 years: stood at -$9.0 million in 2019, then tumbled by 4715.56% to -$434.2 million in 2020, then rose by 16.25% to -$363.7 million in 2021, then rose by 26.8% to -$266.2 million in 2022, then soared by 31.36% to -$182.7 million in 2023.
  • Business Quant data shows Enterprise Value for ALXO at -$182.7 million in Q4 2023, -$190.0 million in Q3 2023, and -$212.8 million in Q2 2023.